Categories
Latest Industry Intelligence
AI in drug discovery eBook out now This 28-page DDW eBook, sponsored by Benchling, contains [...]
From AI to 3D deep-learning research to biologics, Lu Rahman selects some interesting global start-ups [...]
By Dr David C. U’Prichard It is almost axiomatic that the pharmaceutical R&D industry has not achieved in the last decade an increase in productivity (measured as high value NCEs) commensurate with the explosion of new biological information, chemistry techniques and information storage/retrieval/examination systems, let alone the real increase in industry R&D expenditure. In particular, […]
By Michael P. Murphy, MSc Pharmacogenomics offers the opportunity to adopt a new paradigm in drug development. The pharmaceutical industry is faced with a number of challenges including relatively low productivity and success in bringing new drugs to market. Investors demand that pharmaceutical companies deliver several new drugs to the marketplace each year. Additional pressure […]
By Dr Ashok R. Dongre and Dr Stanley A. Hefta The genomic sequencing efforts spawned the field of proteomics by providing the basic blueprint for protein sequences, enabling proteomics to become the contemporary technology for studying the underlying mechanisms of disease. This review will address the technologies related to proteomic research and the application of […]
Harnessing the CRO Intellect By Ian Lennox and Dr Nigel Brown There is no question that pharmaceutical companies are qualified to perform their own discovery and preclinical research. However, to fully exploit the new technologies in the early research phases, to maximise drug leads, and to minimise costs, would the outsourcing to a fully integrated […]
The Genie in the Test Tube – From Gene to Gene Therapy: Part 1 By Dr Jan Steiner For thousands of years, medicine was a descriptive art, with treatments for disease arising from astute observation and trial and error. The rise of modern forms of biological sciences, especially the developments in molecular biology over the […]
Emerging therapeutic vaccines By Marc Hertz, Soren Mouritsen and Anand Gautam The excitement over the past 30 years for immunotherapy of cancer and other diseases has not led to the expected clinical successes. Over-enthusiasts predicted a cure for cancer with the initial development of monoclonal antibody technology, and later the ‘magic bullets’ or toxin-labelled antibodies. […]
HTS a strategy for drug discovery By Dr AR Knight, Cerebrus Ltd Whichever technologies are implemented, high throughput screening is set to become one of the cornerstones of drug discovery, however deciding which strategy to implement will provide many headaches. This article concentrates on screens identifying the interaction of small molecules with protein targets rather […]
Plants as a source of new medicines By Jennie Gwynn and Peter J Hylands Putting aside the excitement surrounding the human genome, in the near future we may well start to see the emergence of a new class of prescription medicine containing complex mixtures of plant extracts. This article discusses the important role that plants […]
The Future Role of CROs By John M Hall PhD and Ludo Reynders PhD The increasing reliance by big pharmaceutical companies on CROs presents a mixture of challenges and opportunities for the industry. Given that the majority of customers are global in their reach, the CRO industry must be prepared to match that reach. Edmund […]
By Matthias Mann, Protein Interaction Laboratory (PIL), University of Southern Denmark Affinity proteomic methods can translate genomic data into validated targets for drug discovery. Baits such as tagged gene product or small molecules obtained from cell-based assays are used to purify interacting proteins. These proteins are then identified by high sensitivity, high throughput mass spectrometric […]